Capricor Therapeutics, Inc. (CAPR) News
Follow Capricor Therapeutics, Inc. (CAPR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 50 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision
Shares of Capricor Therapeutics (CAPR) rose about 8% on Monday after the company said that cardiac results from its HOPE-3 late-stage trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Rese
REGULATION | Nov 09, 2026, 08:13 PM UTC
M
Clinical Investigators Urge FDA to Approve Capricor’s Deramiocel
A public letter from clinical investigators urged FDA approval of Capricor Therapeutics’ Deramiocel. Capricor shares rose roughly 14% on Tuesday; the FDA decision is upcoming.
REGULATION | Nov 03, 2026, 09:58 PM UTC
M
Capricor shares fall 11% as November FDA decision nears
Capricor Therapeutics shares fell 11% Wednesday, extending weeks of declines as investors weighed the odds of FDA approval for its lead therapy, Deramiocel. The FDA is slated to decide in November.
EQUITY | Oct 21, 2026, 07:52 PM UTC
M
CAPR stock rises nearly 5% as Capricor presents Deramiocel data
Capricor Therapeutics’ CAPR shares rose about 5% after the company presented clinical heart data for Deramiocel in Duchenne muscular dystrophy ahead of an anticipated November FDA decision.
EQUITY | Oct 07, 2026, 11:30 PM UTC
H
Capricor Therapeutics BLA Under FDA Review Following Positive HOPE-3 OLE Data
Capricor Therapeutics announced positive data from its HOPE-3 OLE study, demonstrating a 76% slowing of upper limb decline after crossover to Deramiocel. The company has submitted this data as a major amendment to its Bi
REGULATION | Oct 05, 2026, 01:08 PM UTC
M
Capricor Therapeutics Stock Surges 10.5% on Duchenne Data
Capricor Therapeutics (CAPR) shares climbed 10.5% after investors focused on two-year follow-up data for its Duchenne muscular dystrophy therapy, deramiocel, presented at the World Muscle Society congress in Japan.
EQUITY | Oct 01, 2026, 12:03 AM UTC
H
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Wednesday. Shares of Hewlett Packard Enterprise Co (NYSE: HPE ) rose during Wednesday’s session after the company announced it raised its FY27
LIVE | Sep 30, 2026, 01:55 PM UTC
H
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of FingerMotion Inc (NASDAQ: FNGR ) rose sharply in pre-market trading after the company announced it had entered into a definitive Share Purchase Agreement to acquire 100% of Newbit Technology Inc. Under the agre
LIVE | Sep 30, 2026, 09:32 AM UTC
H
Why Are Nasdaq Futures Rising Premarket? MU, TSLA, CAPR, VNDA, ASTS, HOOD, BA Stocks In Focus
U.S. stock futures were higher early Wednesday as investors brace for the Federal Reserve’s preferred inflation metric, the PCE Price Index, alongside Q2 GDP numbers.As of 4:00 a.m. ET, Nasdaq and S&P 500 futures were up
MACRO | Sep 30, 2026, 08:30 AM UTC
L
Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
U.S. stock futures were trading mixed in the overnight session late Tuesday as long-dated bond yields eased back marginally after climbing to multi-decade highs during the day.As of 11:09 p.m. EDT, Dow futures were up 0.
EQUITY | Sep 30, 2026, 03:39 AM UTC
L
Why Did CAPR Stock Jump 20% After-Hours Today?
Shares of Capricor Therapeutics (CAPR) surged 20% in after-hours trading on Tuesday as new Hope-3 extension data showed substantially slower upper-limb deterioration in patients who switched to Deramiocel, boosting the c
REGULATION | Sep 30, 2026, 01:24 AM UTC
L
Piper Sandler raises Capricor Therapeutics price target to $25
Piper Sandler raised its price target on Capricor Therapeutics to $25.00 per share from $2.00, according to Benzinga ratings actions.
EQUITY | Sep 01, 2026, 04:56 PM UTC
L
Yext jumps after better-than-expected Q2 earnings
Yext Inc shares surged 8.4% to $7.34 after reporting Q2 earnings of 21 cents per share, beating the 17 cents consensus, and quarterly sales of $111.103 million versus $111.300 million.
EARNINGS | Sep 01, 2026, 01:54 PM UTC
M
Piper Sandler turns positive on CAPR ahead of FDA DMD decision
Piper Sandler turned positive on Capricor Therapeutics (CAPR), saying potential upside from an FDA approval of its Duchenne muscular dystrophy treatment outweighs downside risk.
REGULATION | Sep 01, 2026, 10:52 AM UTC
L
CAPR shares +27% premarket after FDA headlines
CAPR shares +27% premarket after FDA headlines
REGULATION | Aug 24, 2026, 01:28 PM UTC
M
CAPR FDA extends deramiocel BLA review target to November 22, 2026
Capricor Therapeutics says the FDA has extended the PDUFA target action date for deramiocel BLA review to November 22, 2026.
REGULATION | Aug 24, 2026, 01:26 PM UTC
M
Capricor Therapeutics says FDA extends Deramiocel PDUFA target date
Capricor Therapeutics says the FDA has extended the PDUFA target action date for its deramiocel BLA as the review continues.
REGULATION | Aug 24, 2026, 01:25 PM UTC
H
CAPR: Kaos Capital plans two independent director nominees
Hammerstone MarketTalk says CAPR’s Kaos Capital plans to nominate two independent director candidates at Capricor and asks for an immediate meeting, board change, and a capital-preservation plan, including a board-led M&
MNA | Aug 21, 2026, 11:48 AM UTC
L
Capricor says Deramiocel BLA talks continue with FDA
Capricor Therapeutics says it remains engaged with the FDA on Deramiocel’s BLA after a BIMO inspection produced a Form 483 with one observation that it has addressed.
EARNINGS | Aug 14, 2026, 01:25 PM UTC
L
Cantor upgrades Capricor to Overweight, lifts target to $28
Cantor Fitzgerald upgrades Capricor Therapeutics to Overweight from Neutral and raises its price target to $28 from $3.50 after the Q2 call centered on the negative FDA panel vote for deramiocel.
EARNINGS | Aug 14, 2026, 11:56 AM UTC
L
Analysts raise views on CAPR, DLR, FOXA, LTC, NERV, NYAX
Analysts upgrade CAPR to Overweight at Cantor, DLR to Buy at HSBC, FOXA to Overweight at JPM, LTC to Outperform at RBC, NERV to Buy at Jefferies, and NYAX to Outperform at Keefe.
EQUITY | Aug 14, 2026, 10:28 AM UTC
H
Capricor Therapeutics Stock Drops 64%
Capricor Therapeutics stock plummets after clinical data release
EQUITY | Aug 04, 2026, 10:36 AM UTC
H
Bulls And Bears: Amazon, Microsoft, SpaceX
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks closed a volatile week mixed as investors navigated a hawkish Federal Reserve, surging
EARNINGS | Aug 01, 2026, 12:00 PM UTC
H
CAPR Downgraded to Hold
CAPR downgraded from Buy to Hold
EQUITY | Jul 31, 2026, 11:07 AM UTC
H
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.40% to 51,801.63 while the NASDAQ surged 2.08% to 24,952.56. The S&P 500 also rose,
EARNINGS | Jul 30, 2026, 04:02 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
L
Capricor Therapeutics Faces Investor Lawsuits
Capricor Therapeutics investors face lawsuits
EQUITY | Jul 30, 2026, 03:02 PM UTC
H
Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 600 points on Thursday. Following the market opening Thursday, the Dow traded up 0.69% to 51,951.16 while the NASDAQ surged 2.54% to 25,
EARNINGS | Jul 30, 2026, 02:05 PM UTC
L
CAPR - Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
CAPR - Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
REGULATION | Jul 30, 2026, 01:30 PM UTC
H
CAPR Downgraded to Perform by Oppenheimer
Oppenheimer downgrades CAPR due to dim outlook on deramiocel
EQUITY | Jul 30, 2026, 12:37 PM UTC
H
Piper Sandler Downgrades CAPR
Piper Sandler downgrades CAPR to Neutral
EQUITY | Jul 30, 2026, 12:01 PM UTC
L
CAPR downgraded downgrade to Perform from Outperform and rescind OPCO's $54 PT after FDA Adcom @ OPCO
CAPR downgraded downgrade to Perform from Outperform and rescind OPCO's $54 PT after FDA Adcom @ OPCO
REGULATION | Jul 30, 2026, 12:01 PM UTC
L
CAPR 55% premarket after FDA panel votes against Co's duchenne heart disease therapy
CAPR 55% premarket after FDA panel votes against Co's duchenne heart disease therapy
REGULATION | Jul 30, 2026, 11:35 AM UTC
H
CAPR Downgraded to Neutral
CAPR downgraded to Neutral
EQUITY | Jul 30, 2026, 11:33 AM UTC
H
CAPR Downgraded to Neutral
CAPR downgraded to Neutral by Piper Sandler
EQUITY | Jul 30, 2026, 09:16 AM UTC
L
CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
REGULATION | Jul 29, 2026, 08:51 PM UTC
L
CAPR Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings- Randomized, Double-Bl
CAPR Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings- Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with
REGULATION | Jul 29, 2026, 02:10 PM UTC
L
CAPR Downgrade to Neutral (from Buy), PT to $10 (from $63) @ Briley
CAPR Downgrade to Neutral (from Buy), PT to $10 (from $63) @ Briley
EQUITY | Jul 28, 2026, 01:20 PM UTC
L
CAPR Downgrade from Buy to Neutral at Alliance Global Partners
CAPR Downgrade from Buy to Neutral at Alliance Global Partners
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD Cowen LAUR: UNDERWEIGHT @ MS LEVI: EQUAL WEIGHT @ WFC MPLT: EQUAL WEIGHT @ MS P
EQUITY | Jul 28, 2026, 11:11 AM UTC
H
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in decline amid weakness in tech stocks. Still, the market has reacted positively to easing geopolitical tensions and a steep declin
MACRO | Jul 27, 2026, 03:56 PM UTC
L
CAPR downgrade to neutral from buy, PT to $10 @ BRiley
CAPR downgrade to neutral from buy, PT to $10 @ BRiley
EQUITY | Jul 27, 2026, 03:12 PM UTC
L
B. Riley downgrades Capricor as FDA briefing docs 'incompatible with approval'
B. Riley downgrades Capricor as FDA briefing docs 'incompatible with approval'
REGULATION | Jul 27, 2026, 03:09 PM UTC
L
Capricor says analyses in FDA's briefing materials 'rely on' SAP version 1.1
Capricor Therapeutics...
REGULATION | Jul 27, 2026, 03:05 PM UTC
L
Capricor Therapeutics plunges after FDA posts deramiocel briefing notes
Shares of Capricor...
RATES | Jul 27, 2026, 02:16 PM UTC
L
CAPR premarket lows -21%
CAPR premarket lows -21%
EQUITY | Jul 27, 2026, 11:54 AM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
H
CAPR: FDA Plans Advisory Meeting
Capricor Therapeutics' BLA for Deramiocel is set to be discussed by the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee
EQUITY | Jun 26, 2026, 02:05 PM UTC
H
CAPR: FDA Reviews BLA
Capricor Therapeutics announces FDA advisory committee meeting to review BLA for Deramiocel for Duchenne Muscular Dystrophy treatment
EQUITY | Jun 26, 2026, 02:02 PM UTC
H
CAPR Presents Positive DMD Data
Capricor presents positive five-year HOPE-2 OLE data and HOPE-3 Phase 3 results for Deramiocel in Duchenne Muscular Dystrophy
EQUITY | Jun 26, 2026, 01:05 PM UTC